抗乙型肝炎病毒新药——阿德福韦酯的研究进展

阿德福韦酯(adefovir)是新一代核苷类抗病毒药物,能够有效抑制逆转录病毒、嗜肝病毒和疱疹病毒等各种病毒的复制和表达。实验研究表明阿德福韦酯不仅对野生HBV有效,对拉米夫定耐药的HBV病毒株也有显著的抑制作用,提示其能够作为拉米夫定耐药病毒感染的补充、替代产品,成为解决乙型肝炎病毒核苷类似物耐药问题的有效办法。阿德福韦酯有望成为联合治疗乙型肝炎的药物之一,可用于两种或多种药物的联合或序贯应用等方式治疗慢性乙型肝炎或HBV／HIV-1的合并感染。本文主要从阿德福韦酯的作用机制、药效毒理、临床药物动力学、体内抗病毒作用、耐药监测、临床用药的安全性等作一总结。

Advances in Study on Anti-hepatitis B Virus New Drug: Adefovir Dipivoxil

Adefovir dipivoxil(ADV)is new generation nucleoside anti-virus drug,which is able to effectively repress the replication and expression of virus,such as retroviru, hepadnavirus and herpesviruses.Studies have shown that ADV may not only fight effectively against wild HBV but that it may obviously restrain hepatitis B virus resistant to lamivudine. This indicates that ADV can be used as substitute and supplement to cure virus infection resistant to lamivudine,becoming an effective approach to solve resistant problem of hepatitis B virus nucleoside analogues.ADV is hoped to become one of medicines to treat hepatitis B, which may be used for combination therapy or seqential therapy of two kinds or various medicines to cure chronic hepatitis B or HBV/HIV-1 infection.The purpose of this review is to draw the attention to mechanism, pharmacodynamics, toxicology, pharmacokinetics,anti-virus, resistance monitor, clinical medicine safety of ADV.